These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35503989)

  • 21. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
    Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
    J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
    Sim DS; Jeong MH; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY;
    J Cardiol; 2019 Feb; 73(2):142-150. PubMed ID: 30509351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Hu X; Wang W; Ye J; Lin Y; Yu B; Zhou L; Zhou Y; Dong H
    Biomed Pharmacother; 2021 Nov; 143():112196. PubMed ID: 34560551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.
    Vos NS; Amoroso G; Vink MA; Maarse M; Adams R; Herrman JR; Patterson MS; van der Schaaf RJ; Slagboom T; de Winter RJ
    J Invasive Cardiol; 2018 Dec; 30(12):431-436. PubMed ID: 30318484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.
    Ghonim AA; Mostafa A; Emara A; Algazzar AS; Qutub MA
    Cardiovasc J Afr; 2019 Sep/Oct 23; 30(5):285-289. PubMed ID: 31194213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
    Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
    J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
    Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Wang X; Li X; Wu H; Li R; Liu H; Wang L; Bai S; Zhang L; Chen T; Liu J; Li Q; Du R
    Coron Artery Dis; 2019 Aug; 30(5):317-322. PubMed ID: 30614823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
    Tatlisu MA; Kaya A; Keskin M; Uzman O; Borklu EB; Cinier G; Hayiroglu MI; Eren M
    Coron Artery Dis; 2016 Nov; 27(7):543-50. PubMed ID: 27341666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
    Rigattieri S; Lettieri C; Tiberti G; Romano M; Ferlini M; Testa L; Pierini S; Ettori F; Passamonti E; Marchese A; Musumeci G; Esposito G; Tarantini G
    J Interv Cardiol; 2022; 2022():9609970. PubMed ID: 35418809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
    Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.